CVM-1118 combined with Nivolumab for advanced liver cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 2 trial investigates the efficacy of CVM-1118, a new anti-cancer drug, in combination with Nivolumab, a checkpoint inhibitor, for patients with unresectable advanced hepatocellular carcinoma. The study aims to evaluate how well this combination therapy works in promoting cancer cell death and inhibiting tumor growth, particularly in patients who have not responded to previous treatments. The safety of CVM-1118 has already been established in earlier studies, and this trial will further explore its potential benefits when paired with Nivolumab. Participants will be closely monitored for treatment effects and safety outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18+ (20+ for subjects in Taiwan)
* Diagnosis of hepatocellular carcinoma

  * Pathologically or cytologically-confirmed or clinically diagnosed in accordance with American Association for the Study of Liver Diseases (AASLD) criteria (i.e., radiologic imaging with cross-sectional multiphasic contrast CT or MRI showing a ≥ 1 cm liver lesion)
* Subjects with advanced-stage, unresectable hepatocellular carcinoma that is not appropriate for potentially curable therapy who have progressed from, been intolerant of prior systemic anti-cancer therapies (e.g., sorafenib, lenvatinib, atezolizumab in combination with bevacizumab).
* Barcelona Clinic Liver Cancer (BCLC) stage B not appropriate for or with disease progression after local regional therapy, or BCLC stage C
* Child-Pugh liver function class A
* Measurable disease (per mRECIST)
* ECOG performance status of 0 to 1
* Adequate laboratory parameters including:

  * AST and ALT ≤ 3.0 x ULN (≤ 5.0 x ULN if due to liver involvement)
  * Total serum bilirubin ≤ 2.0 x ULN (≤ 3.0 x ULN for subjects with documented Gilbert's syndrome)
  * ANC ≥1500/µL
  * Platelets ≥ 90,000/µL
  * HGB ≥ 9.0 g/dL
  * Serum creatinine clearance of ≥ 50 mL/min based on Cockcroft-Gault formula
  * Serum albumin ≥ 2.8 gm/dL
  * INR ≤ 2.3
  * PT/aPTT ≤ 1.2 x ULN
* QTcF ≤ 480 msec
* Subjects are eligible to enroll if they have HBV-, or HCV-HCC, defined as follows:

  * Chronic HBV infection as evidenced by detectable HBV DNA or HBsAg. Subjects with chronic HBV infection must be on antiviral therapy and have HBV DNA \<500 IU/mL. If not on an antiviral therapy at screening, then subjects must be willing to start the antiviral therapy at the time of consent.
  * Active or resolved HCV infection as evidenced by detectable HCV RNA or antibody.

Exclusion Criteria:

* HCC with portal vein invasion at the main portal branch (Vp4)
* Known history of esophageal varices or gastrointestinal bleeding within the past 3 months
* Prior immunotherapy for hepatoma
* ≤ 7 days from prior limited field palliative irradiation therapy and C1D1
* ≤ 28 days from prior irradiation therapy and C1D1
* ≤ 14 days (or 5 half-lives) from prior systemic anticancer therapy and C1D1
* ≤ 28 days from local regional therapy (e.g., trans-arterial embolization, radiofrequency ablation) and C1D1
* Presence of other active cancer(s) likely to require treatment in the next two (2) years or likely to impact the assessment of any study endpoints
* Active bacterial or fungal infection(s) requiring systemic therapy within 7 days prior to C1D1
* Known CNS metastases
* Known history of HIV infection
* Females who are currently pregnant or breast-feeding
* Known gastrointestinal disease that may significantly alter the absorption of oral medications
* Psychiatric illness or social situation that would interfere with compliance with study requirements
* History of clinically significant cardiovascular abnormalities

Where it's running

• Kaohsiung Chang Gung Memorial Hospital
  Kaohsiung City, Taiwan Recruiting
• Keelung Chang Gung Memorial Hospital
  Keelung, Taiwan Recruiting
• National Cheng Kung University Hospital
  Tainan, Taiwan Recruiting
• National Taiwan University Hospital
  Taipei, Taiwan Recruiting
• Taipei Veterans General Hospital
  Taipei, Taiwan Recruiting

Study contacts

• Principal investigator: Pei-Jer Chen, MD/PhD — National Taiwan University Hospital
• Study coordinator: Yen-Ling Chen, PhD
• Email: yenlingchen@trx.com.tw
• Phone: 886-2-2653-5007

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Oral Alintegimod with Ipilimumab followed by Nivolumab for advanced cancer

  This study is testing if a new oral medication called Alintegimod, combined with two other cancer treatments, can help people with advanced solid tumors feel better and live longer.

  Recruiting at 4 sites Phase 1/2 7 Hills Pharma, LLC · Aurora, Colorado and 4 other locations · NCT06362369

• Givastomig with nivolumab and chemotherapy for CLDN18.2-positive metastatic stomach or gastroesophageal junction cancer

  This study will see if adding givastomig to nivolumab plus standard chemotherapy helps adults with CLDN18.2- and PD-L1-positive metastatic stomach or gastroesophageal junction cancer live longer without their disease getting worse.

  Recruiting at 5 sites Phase 2 I-Mab Biopharma US Limited · Goodyear, Arizona and 5 other locations · NCT07432295

• Combining two immunotherapy drugs for MSI-H/dMMR advanced stomach and gastroesophageal junction cancer

  This trial will try two immunotherapy drugs (balstilimab and botensilimab) as first treatment for adults with MSI‑H/dMMR, HER2‑negative advanced or metastatic stomach or gastroesophageal‑junction cancer whose tumors have PD‑L1 CPS ≥5, and will compare that to standard chemotherapy with nivolumab.

  Recruiting at 7 sites Phase 3 Centre Leon Berard · Brest and 6 other locations · NCT06346197

• Comparing home and clinic administration of nivolumab for cancer treatment

  This study tests whether giving cancer patients their treatment at home instead of in a clinic makes them feel better and prefer their care more.

  Recruiting Phase 2 Mayo Clinic · Jacksonville, Florida · NCT06265285

• Testing MGC026 in patients with advanced solid tumors

  This study is testing a new treatment called MGC026 to see if it can help adults with advanced solid tumors that can't be removed or have spread to other parts of the body.

  Recruiting at 12 sites Phase 1 MacroGenics · Los Angeles, California and 11 other locations · NCT06242470

• Combination treatment for advanced clear cell kidney cancer

  This study is testing a new combination of treatments for people with advanced clear cell kidney cancer to see if it is safe and effective.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT05663710

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.